Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Northwest Biotherapeutics, Inc. (NWBO : OTC)
 
 • Company Description   
Northwest Biotherapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing immunotherapy products that safely generate and enhance immune system responses to treat cancer.

Number of Employees: 25

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.22 Daily Weekly Monthly
20 Day Moving Average: 1,950,252 shares
Shares Outstanding: 1,458.60 (millions)
Market Capitalization: $325.27 (millions)
Beta: -1.12
52 Week High: $0.48
52 Week Low: $0.17
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.23% -17.44%
12 Week -36.65% -46.71%
Year To Date -18.85% -24.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4800 MONTGOMERY LANE SUITE 800
-
BETHESDA,MD 20814
USA
ph: 240-497-9024
fax: 240-627-4121
lgoldman@nwbio.com http://www.nwbio.com
 
 • General Corporate Information   
Officers
Linda F. Powers - Chief Executive Officer;President and Chairperson
Alton L. Boynton - Director
Navid Malik - Director
Pat Sarma - Director
J. Cofer Black - Director

Peer Information
Northwest Biotherapeutics, Inc. (CORR.)
Northwest Biotherapeutics, Inc. (RSPI)
Northwest Biotherapeutics, Inc. (CGXP)
Northwest Biotherapeutics, Inc. (BGEN)
Northwest Biotherapeutics, Inc. (GTBP)
Northwest Biotherapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 66737P600
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/08/25
Share - Related Items
Shares Outstanding: 1,458.60
Most Recent Split Date: 9.00 (0.06:1)
Beta: -1.12
Market Capitalization: $325.27 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 220.82
EPS Growth
vs. Year Ago Period: 50.00%
vs. Previous Quarter: 50.00%
Sales Growth
vs. Year Ago Period: 32.04%
vs. Previous Quarter: 62.34%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -303.49
12/31/24 - -296.98
Current Ratio
06/30/25 - -
03/31/25 - 0.06
12/31/24 - 0.06
Quick Ratio
06/30/25 - -
03/31/25 - 0.06
12/31/24 - 0.06
Operating Margin
06/30/25 - -
03/31/25 - -5,757.57
12/31/24 - -6,062.08
Net Margin
06/30/25 - -
03/31/25 - -5,757.57
12/31/24 - -6,062.08
Pre-Tax Margin
06/30/25 - -
03/31/25 - -5,757.57
12/31/24 - -6,062.08
Book Value
06/30/25 - -
03/31/25 - -0.07
12/31/24 - -0.07
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©